The ecosystem for conducting oncology clinical trials in India is rapidly evolving, promising to expedite the introduction of best-in-class drugs to Indian patients within the next decade. This progress is driven by significant advancements in cancer research and therapy development, according to Dr. Uday Saxena, Chair, Product Development at Bharath Advanced Therapeutics and Executive Secretary, Federation of Asian Biotech Associations.
Advancements in Cancer Therapies
The number of companies focused on developing novel cancer therapies has steadily increased over the past decade. Notably, CAR-T therapies, previously exclusive to developed nations, are now being developed and launched in India at approximately 10% of the cost compared to other countries. Furthermore, advanced targeted drugs with fewer side effects are under active development, offering a more patient-friendly alternative to traditional cytotoxic drugs that often cause severe side effects such as nausea, hair loss, and weight loss.
Collaborative Efforts and Innovative Programs
India is partnering with the United States in the 'moon shot' therapy development program, which aims not only to treat cancer but to cure and ultimately eradicate the disease. The availability of CAR-T therapy in India demonstrates that treatment options are now on par with global standards. Additionally, a vaccine to prevent cervical cancer is slated for imminent launch.
Shift Towards Oral Targeted Drugs
The pipeline of targeted oral drugs, as opposed to injectable versions, suggests that domestically developed treatment options could transform India from a cancer capital to a cancer cure capital. Dr. Saxena noted a remarkable shift in the last five years, with local companies equipping themselves to remain competitive in the race to treat cancer.
Highlights from Cancer Next 2024
The recent Cancer Next 2024 conference showcased revolutionary oncology research efforts from Indian institutions and companies. Bharat Advanced Therapeutics, for instance, presented preclinical data on BAT150030, a novel oral targeted therapy for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), demonstrating complete tumor regression in xenograft models. BAT150030 is expected to enter first-in-human trials by 2025, offering new hope for leukemia patients.
Serum Institute of India also presented results from nationwide HPV vaccine trials designed to significantly reduce cervical and oropharyngeal cancers. This vaccine targets both boys and girls, addressing major public health concerns.
ImmunoACT showcased impressive outcomes from its CAR-T therapy, achieving an 80% remission rate among over 200 patients. Priced at just $50,000 per treatment in India, compared to $500,000 internationally, this therapy sets a new benchmark for affordability.
Aurigene Oncology highlighted the successful licensing of oncology molecules to global pharmaceutical leaders, underscoring India’s growing influence in drug discovery and development. VeGen Therapeutics is also developing targeted therapies for various cancers.
Cancer NEXT 2024, organized by Dr. P Reddanna and Dr. Markendeya Gorantla, reaffirmed India’s potential to lead global cancer research by addressing challenges and delivering innovative, affordable solutions for patients. The conference also showcased numerous new diagnostic tools under development, fostering partnerships and promoting advanced sciences to ensure quality cancer care is accessible to all.
